Publications by authors named "Catherine Royce"
Background: Palliative care, a recognised component of care by the World Health Organization is poorly developed in low- and middle-income countries. Mobile phone technology, an effective way to increase access and sustainability of healthcare systems globally, has demonstrated benefits within palliative care service delivery, but is yet to be utilised in Ethiopia.
Aim: To co-design, develop and evaluate a mobile phone based remote monitoring system for use by palliative care patients in Ethiopia.
Background: AmBisome® is an efficacious, safe anti-leishmanial treatment. There is growing interest in its use, either as a single dose or in combination treatments. In East Africa, the minimum optimal single-dosage has not been identified.
View Article and Find Full Text PDFBackground: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard dose of 15 mg/kg/day of paromomycin sulphate (PM) for 21 days was not efficacious in patients in Sudan. We therefore decided to test the efficacy of paramomycin for a longer treatment duration (15 mg/kg/day for 28 days) and at the higher dose of 20 mg/kg/day for 21 days.
Methods: This randomized, open-label, dose-finding, phase II study assessed the two above high-dose PM treatment regimens.
Article Synopsis
- Visceral leishmaniasis (VL) is a serious health concern in developing countries, with limited and costly treatment options, highlighting the urgent need for better therapies.
- A clinical trial compared paromomycin (PM) and sodium stibogluconate (SSG) as treatments for VL in East Africa, but PM had significantly lower cure rates (63.8%) compared to SSG (92.2%) and was less effective in Sudan specifically.
- The study concluded that the effectiveness of PM at its tested dosage was insufficient, particularly in Sudan, indicating that further research on higher doses and combination therapies is necessary.
During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). The World Health Organization convened a workshop to review current knowledge and to develop guidelines for liposomal amphotericin B use for VL. In Europe, liposomal amphotericin B is widely used to treat VL.
View Article and Find Full Text PDFHalf a million new cases of visceral leishmaniasis occur each year, and 10% of these are fatal. New tools are urgently needed for mapping, diagnosing, and treating the disease.
View Article and Find Full Text PDF